Chardan Capital Markets analyst Keay Nakae initiates coverage on SAB Biotherapeutics (NASDAQ: SABS) with a Buy rating and a price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE